UPDATE: Morgan Stanley Reiterates On Celgene On AG-221 Potential

In a report published Monday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Celgene CELG, but removed the $150.00 price target. In the report, Morgan Stanley noted, “Agios' AG-221 is a targeted therapy for AML (IDH2m or ~15% of all AML) which Celgene recently exercised its option for global commercial rights (owes Agios a low double digit royalty). EHA data incl. 35 pts up from 10 at AACR. EHA responses (ORR) were 44% (14/32, 19% CR with 3 pts not yet at day 28) down from 60% (6/10, 30% CR) at AACR. Pts with CRs achieved 2.5+ mos of duration. "Our conclusions: (1) AG-221 is clearly active. Hwr, given that IDH2m is a favorable marker that confers longer PFS, we believe the larger sample size at EHA more closely represents its true activity than the data at AACR; (2) The path to market appears clear and we would not be surprised to see break-through therapy designation given the target and responses; (3) Commercially, this is a small indication with ~2,500-5,000 US pts. AG-221's potential value to Celgene comes from expanding into other cancers with IDH2m (MDS, NHL) where we expect 2H cohorts.” Celgene closed on Friday at $159.99.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsMatthew HarrisonMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!